Healthcare and hospitals in India: beds, ARPOB, and the diagnostic chain

India's healthcare infrastructure gap

The structural investment thesis for India's private healthcare sector begins with a simple fact: India has historically had far fewer hospital beds per 1,000 population than most comparable economies. World Health Organisation data and government estimates placed India's hospital bed density at approximately 1.3–1.5 beds per 1,000 people — compared to around 4–5 beds per 1,000 in China, 6 per 1,000 in Germany, and nearly 3 per 1,000 even in lower-middle-income countries with more developed public health systems. Only a fraction of those beds were in the private organised sector; a large share were in public hospitals that are typically overcrowded and under-resourced.

The implications for listed private hospital companies were straightforward: demand for quality inpatient care significantly exceeded supply at organised private hospitals, providing structural pricing power and growth runway as the middle class expanded and insurance penetration increased. Unlike sectors where capacity additions create oversupply, hospital capacity expansion in most Indian cities was absorbed by latent unmet demand rather than creating price competition — at least for quality tertiary and super-specialty hospitals in the 2010s and early 2020s.

This demand-supply imbalance drove the strategy of India's largest hospital chains — expanding bed count, adding new hospitals in under-served cities, and building specialty depth in high-revenue clinical areas. Bed count growth was the primary volume metric, while the quality of care and case mix driven by specialist recruitment determined revenue intensity.

How a hospital makes money: the OPD-IPD-surgery funnel

A hospital's revenue generation follows a predictable funnel structure, and understanding this funnel is essential to reading a hospital company's financials.

Outpatient Department (OPD)

OPD consultations are the top of the funnel. Patients visit specialist doctors for initial diagnosis, follow-up care, second opinions, or prescription services. OPD revenue comes from consultation fees, which are retained partly by the hospital and partly paid to the visiting or employed specialist. OPD is also where diagnostic tests are ordered — blood panels, imaging, biopsies — generating ancillary revenue for the hospital's in-house laboratory and radiology department.

OPD volumes are a leading indicator of future IPD demand — a hospital that has built a strong OPD patient flow across multiple specialties has a feed pipeline into its higher-revenue inpatient beds. Specialist doctor footprint (the number and reputation of specialists attached to the hospital) is the primary driver of OPD volumes.

Inpatient Department (IPD)

IPD admissions occur when a patient requires overnight or extended care, observation, or treatment that cannot be managed in OPD. IPD revenue includes room charges (general ward, semi-private, private, ICU — each at progressively higher room rates), nursing care charges, in-house diagnostics, pharmacy dispensing, and specialist visit charges. IPD is the backbone of hospital revenue — for most large Indian hospital chains, IPD accounted for 65–75% of total revenue.

Occupancy rate — the percentage of available beds occupied at any given time — is the primary volume metric for IPD. A hospital running at 70–75% occupancy is near efficient operation; occupancy below 60% suggests significant fixed cost underutilisation; occupancy above 85–90% means the hospital is effectively capacity-constrained and growth requires new bed additions.

Surgical procedures

Surgical procedures are the highest-revenue category within IPD. A cardiac bypass surgery, a cancer resection, a hip replacement, or a liver transplant generates significantly more revenue than a comparable length-of-stay medical admission. Revenue from surgical cases includes the operating room charges, surgical consumables (implants, stents, disposables), anaesthesia charges, ICU time, and post-operative monitoring.

ARPOB is directly influenced by the surgical mix — what proportion of IPD days are surgical versus medical admissions, and what the complexity of surgical cases is. A hospital that has built strong cardiac surgery, oncology, and neurosurgery programs will generate substantially higher ARPOB than a general medicine hospital at the same occupancy rate.

Key metrics for analysing a hospital company

ARPOB (Average Revenue Per Occupied Bed)

ARPOB is the most widely quoted revenue quality metric in Indian hospital analysis. It is calculated as total inpatient revenue divided by total occupied bed-days. Rising ARPOB over time indicates either improved case mix (more complex surgeries), price increases, or both. Declining ARPOB could indicate mix dilution from lower-complexity cases or pricing pressure from insurers. Among India's leading hospital chains, ARPOB varied widely — super-specialty urban hospitals had significantly higher ARPOB than tier-2 and tier-3 city hospitals run by the same chain, reflecting differences in case mix and local market pricing.

Occupancy rate

Occupancy rate measures how well the fixed bed capacity is being utilised. Because hospital fixed costs (building, equipment, nursing staff, administration) are high relative to the variable cost of treating an additional patient, operating leverage is significant — each incremental occupied bed contributes strongly to EBITDA once the hospital has passed its breakeven occupancy level. New hospitals in a chain typically had low occupancy and operated at a loss in their first two to three years before ramping up to mature occupancy levels.

EBITDA per bed

EBITDA per bed is an efficiency metric that normalises profitability by the scale of the asset base. It allows comparison across hospital chains of different sizes. A chain with 1,000 beds generating ₹2 crore EBITDA per bed per year is more efficient than one with 3,000 beds generating ₹1 crore EBITDA per bed. EBITDA per bed improves with ARPOB growth, occupancy improvement, and cost management.

Payor mix

The breakdown of revenue across private insurance, government insurance (Ayushman Bharat, state schemes, CGHS, ECHS for defence personnel), and out-of-pocket (self-pay) patients significantly affects ARPOB and margin. Government-scheme patients are reimbursed at package rates set by the government — which were historically lower than private insurance or self-pay rates for the same procedure. Hospitals with a higher share of government-scheme revenue therefore reported lower overall ARPOB than peers with more private payor exposure.

ALOS (Average Length of Stay)

ALOS measures the average number of days a patient stays in the hospital per admission. ALOS is influenced by clinical complexity, discharge protocols, and the share of surgical versus medical cases. Shorter ALOS, all else equal, means more patient throughput from the same bed — higher bed turnover and potentially higher annual revenue per bed. Clinical quality programmes focused on faster recovery, day-care surgical procedures (where the patient is admitted and discharged the same day), and efficient discharge planning all work to reduce ALOS.

Major listed hospital chains

Apollo Hospitals Enterprisewas India's largest private hospital chain by market capitalisation as of the early 2020s, with a multi-site network spanning major metros and several tier-2 cities. Apollo built its brand on high-complexity cardiac, cancer, and transplant programmes and had a significant international patient inflow from the Middle East and Southeast Asia. Apollo also operated a standalone pharmacy retail business (Apollo Pharmacy), creating a vertical that added revenue outside the core hospital segment.

Max Healthcare(Max India's hospital business, subsequently restructured) was a major presence in Delhi NCR and had been building a pan-India footprint through acquisitions and greenfield additions. Its ARPOB trajectory was among the higher in the sector given its concentration in super-specialty urban care.

Fortis Healthcarewent through a prolonged period of management and corporate governance issues before stabilising under new promoter IHH Healthcare (a Malaysian hospital group) from around 2018 onward. IHH's entry was seen as bringing management stability and operational improvement discipline. Fortis operated hospitals and diagnostic labs across multiple cities.

Narayana Hrudayalaya built its reputation on a different model — high-volume, lower-cost cardiac surgery, pioneered by its founder Dr Devi Shetty at the Narayana Health City in Bengaluru. The model was based on the insight that assembly-line high-volume surgery could drive down the cost per procedure through specialisation and scale while maintaining quality — allowing the hospital to perform cardiac surgeries at costs significantly below urban private hospital benchmarks. NH expanded into other specialties and geographies, including the CTBF hospital in the Cayman Islands for international patients.

Aster DM Healthcare had a distinctive footprint across both India (primarily south India) and the GCC (Gulf Cooperation Council) countries — clinics and hospitals in UAE, Oman, Bahrain, Kuwait, and Qatar. The GCC operations historically generated higher ARPOB than comparable Indian facilities, but also carried currency and geopolitical exposure. The company explored a partial restructuring of its GCC ownership in the mid-2020s.

Global Health Limited (Medanta) operated premium super-specialty hospitals including the flagship Medanta - The Medicity in Gurugram, which became known for its cardiac, cancer, neurosciences, and organ transplant programmes.

Ayushman Bharat: volume vs ARPOB trade-off

Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), launched in September 2018, was designed to provide health insurance coverage of ₹5 lakh per year to approximately 50 crore beneficiaries from economically vulnerable households — making it the world's largest government-funded health insurance programme by coverage.

For private hospitals, PM-JAY created a large new addressable patient population that was previously unable to afford private hospital care. Empanelled hospitals could admit PM-JAY beneficiaries for defined procedures and claim reimbursement at government-notified package rates. The package rates varied by procedure type and state but were consistently reported by hospital operators as below the rates they would charge private insurance or self-pay patients for the same procedure — in some cases materially so.

The practical impact on individual hospital companies depended heavily on their location and existing capacity utilisation. A hospital in a tier-2 city with 55% occupancy and significant spare capacity had every incentive to accept PM-JAY volumes — the incremental revenue from otherwise empty beds added directly to EBITDA even at below-rack rates, as fixed costs were already sunk. A premium metro hospital running at 85% occupancy faced an opportunity cost calculation — every PM-JAY bed displaced a potentially higher-paying private insurance patient. Metro hospitals with high capacity utilisation generally maintained selective PM-JAY empanelment focused on specific procedures where economics were workable.

Diagnostics: the pathology and radiology chain

Diagnostics — laboratory pathology and radiology — is a large and structurally growing segment of Indian healthcare, structurally distinct from hospitals in its business model.

Pathology includes blood tests (complete blood count, lipid profile, thyroid function, HbA1c, infectious disease panels like dengue/COVID), urine analysis, cultures, biopsies and histopathology. Radiology includes imaging tests — X-rays, ultrasounds, CT scans, MRI. Both are driven by physician referrals from OPD consultations, hospital admissions, and preventive health check-ups.

The economics of diagnostics are hub-and-spoke. Large central reference laboratories process complex tests that require expensive equipment and specialist pathologists. A network of satellite collection centres and patient service points (PSPs) collects samples in proximity to patients and sends them to the central lab for processing. The more samples flowing into the central lab, the better the utilisation of expensive machines and reagents, improving profitability.

Dr Lal PathLabswas India's largest listed diagnostics company, operating a hub-and-spoke network primarily concentrated in north India but expanding nationally. It offered a portfolio of tests from routine panels to complex specialised tests.Metropolis Healthcare was another large listed player, with stronger presence in Maharashtra, south India, and international markets. Thyrocare Technologies (acquired by API Holdings, the PharmEasy parent, in 2021) was known for its ultra-low-cost wellness testing model using a highly automated B2B sample collection network. The diagnostics sector saw significant competitive intensity from hospital chains with in-house labs and from new digital-first platforms that aggregated test bookings across multiple labs.

Key metrics for diagnostics companies include revenue per patient, test volume growth, realization per test, and EBITDA margin (diagnostics companies with scale historically delivered EBITDA margins in the 20–30% range).

Pharmacy retail

Organised pharmacy retail was a structurally under-penetrated market in India — the majority of medicines were historically dispensed through small, independent pharmacies rather than organised chains.Apollo Pharmacy(part of Apollo Hospitals group) was India's largest organised pharmacy chain, operating thousands of outlets. MedPlus Health Services was another large listed pharmacy retailer with a concentration in south India.

Pharmacy retail economics were driven by prescription medicines (regulated pricing under DPCO — Drug Price Control Order for essential medicines, unregulated for others), OTC (over-the-counter) products, and increasingly by adjacencies like diagnostics sample collection, health and wellness products, and digital health services. Gross margins in pharmacy retail were historically thin (8–12%) compared to diagnostics or hospitals, making operating leverage critical — high same-store sales growth on a fixed-cost base was the path to EBITDA improvement.

Medical devices

India's medical devices sector was historically import-dependent — most high-end devices (imaging equipment, cardiac devices, surgical instruments, implants) were imported from global manufacturers like Medtronic, Philips, GE, and Siemens Healthineers. The government introduced PLI (Production Linked Incentive) schemes for medical devices to promote domestic manufacturing. Listed Indian medical device companies included Poly Medicure (single-use medical devices, IV cannulas, dialysis consumables) and Skanray Technologies (medical imaging equipment). The domestic manufacturing base was growing but remained small relative to the overall device market size.

Nifty 500 companies in this sector

The Nifty 500 universe includes several listed healthcare companies across hospitals, diagnostics, pharmacy, and medical devices. Explore their financial profiles and historical data in the healthcare stocks section of our stocks directory. Notable listed names included Apollo Hospitals Enterprise, Max Healthcare, Fortis Healthcare, Narayana Hrudayalaya, Aster DM Healthcare, Global Health (Medanta), Dr Lal PathLabs, Metropolis Healthcare, MedPlus Health Services, and Poly Medicure.

To understand how profitability metrics like ROE and ROCE apply to asset-heavy hospital businesses, see our P/E ratio explainer for context on valuation frameworks across capital-intensive sectors.

This primer is educational only and does not constitute investment advice, a recommendation to buy or sell any security, or research under SEBI (Research Analysts) Regulations, 2014. All historical figures and examples are illustrative and reflect past conditions; healthcare businesses carry regulatory, reimbursement, clinical, and operational risks. Past performance is not indicative of future results. Please consult a SEBI-registered investment adviser before making any investment decision.